Manufacturing CapabilityThe acquisition expands BioNTech's manufacturing capability due to CureVac's state-of-the-art research and manufacturing site in Tübingen.
Regulatory ApprovalBioNTech SE has been granted Orphan Drug Designation for a recombinant bispecific antibody for the treatment of small cell lung cancer, providing for seven years of market exclusivity post-approval.
Strategic AcquisitionThe acquisition of CureVac by BioNTech is viewed as a strategic move to eliminate legal and financial uncertainties related to ongoing litigation over mRNA intellectual property.
Bears Say
Clinical Data RisksRisks include negative data for BNT122, BNT111, BNT113, BNT116, BNT211, BNT316, BNT323, and BNT327.
Market UptakeRisks include slower-than-expected market uptake and failure to advance other programs in a timely manner.
What was BioNTech SE’s price range in the past 12 months?
BioNTech SE lowest stock price was $76.53 and its highest was $131.49 in the past 12 months.
What is BioNTech SE’s market cap?
BioNTech SE’s market cap is $25.65B.
When is BioNTech SE’s upcoming earnings report date?
BioNTech SE’s upcoming earnings report date is Aug 04, 2025 which is in 32 days.
How were BioNTech SE’s earnings last quarter?
BioNTech SE released its earnings results on May 05, 2025. The company reported -$2.04 earnings per share for the quarter, beating the consensus estimate of -$2.701 by $0.66.
BioNTech SE pays a Notavailable dividend of $2.111 which represents an annual dividend yield of N/A. See more information on BioNTech SE dividends here
What is BioNTech SE’s EPS estimate?
BioNTech SE’s EPS estimate is -2.12.
How many shares outstanding does BioNTech SE have?
BioNTech SE has 246,236,000 shares outstanding.
What happened to BioNTech SE’s price movement after its last earnings report?
BioNTech SE reported an EPS of -$2.04 in its last earnings report, beating expectations of -$2.701. Following the earnings report the stock price went down -3.659%.
Which hedge fund is a major shareholder of BioNTech SE?
Currently, no hedge funds are holding shares in BNTX
BioNTech SE is a German biotechnology company that focuses on developing and manufacturing active immunotherapies for patient-specific approaches to the treatment of serious diseases. The company is renowned for its work in the field of mRNA-based therapies, particularly in oncology, infectious diseases, and rare diseases. BioNTech gained global recognition for its collaboration with Pfizer to develop one of the first mRNA-based COVID-19 vaccines, known as Comirnaty.
BNTX Company Deck
BNTX Earnings Call
Q1 2025
1.0x
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a company that is making significant progress in its oncology programs and maintaining a strong financial position, despite experiencing decreased revenue and a higher net loss. The strategic investments in developing new therapies and preparing for future product launches are promising, but the financial losses and settlement expenses are notable challenges.Read More>